Browsing by author "Banerji, Udai"
Now showing items 1-20 of 74
-
A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer.
Milton, CK; Self, AJ; Clarke, PA; Banerji, U; Piccioni, F; et al. (AMER ASSOC CANCER RESEARCH, 2020-07-01)KRAS mutation is a key driver of pancreatic cancer and PI3K pathway activity is an additional requirement for Kras-induced tumorigenesis. Clinical trials of PI3K pathway inhibitors in pancreatic cancer have shown limited ... -
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
Dean, E; Banerji, U; Schellens, JHM; Krebs, MG; Jimenez, B; et al. (SPRINGER, 2018-05-01)PURPOSE: AZD5363 is a potent pan-AKT inhibitor originally formulated as a capsule; a tablet was developed for patient convenience and manufacturing ease. This study assessed the PK comparability of both formulations (Part A) ... -
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Kristeleit, R; Plummer, R; Jones, R; Carter, L; Blagden, S; et al. (SPRINGERNATURE, 2023-07-27)BACKGROUND: This was a first-in-human Phase 1/2 open-label dose-escalation study of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737. METHODS: Patients with advanced solid tumours enrolled in dose-escalation cohorts ... -
A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.
Halford, S; Veal, GJ; Wedge, SR; Payne, GS; Bacon, CM; et al. (AMER ASSOC CANCER RESEARCH, 2023-04-14)PURPOSE: Inhibition of monocarboxylate transporter (MCT) 1-mediated lactate transport may have cytostatic and/or cytotoxic effects on tumor cells. We report results from the dose-escalation part of a first-in-human trial ... -
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer.
Kolinsky, MP; Rescigno, P; Bianchini, D; Zafeiriou, Z; Mehra, N; et al. (ELSEVIER, 2020-02-21)BACKGROUND: Activation of the PI3K/AKT/mTOR pathway through loss of phosphatase and tensin homolog (PTEN) occurs in approximately 50% of patients with metastatic castration-resistant prostate cancer (mCRPC). Recent evidence ... -
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.
Banerji, U; Dean, EJ; Pérez-Fidalgo, JA; Batist, G; Bedard, PL; et al. (AMER ASSOC CANCER RESEARCH, 2017-10-24)Purpose: This phase I, open-label study (Study 1, D3610C00001; NCT01226316) was the first-in-human evaluation of oral AZD5363, a selective pan-AKT inhibitor, in patients with advanced solid malignancies. The objectives ... -
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson, D; Griffin, MJ; Sludden, J; Drew, Y; Cresti, N; et al. (ELSEVIER SCI LTD, 2016-11-01)PURPOSE: We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, ... -
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.
Banerjee, S; Michalarea, V; Ang, JE; Ingles Garces, A; Biondo, A; et al. (AMER ASSOC CANCER RESEARCH, 2022-11-01)PURPOSE: CT900 is a novel small molecule thymidylate synthase inhibitor that binds to α-folate receptor (α-FR) and thus is selectively taken up by α-FR-overexpressing tumors. PATIENTS AND METHODS: A 3+3 dose escalation ... -
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.
Vormoor, B; Veal, GJ; Griffin, MJ; Boddy, AV; Irving, J; et al. (WILEY, 2017-06-01)Aurora kinases regulate mitosis and are commonly overexpressed in leukemia. This phase I/IIa study of AT9283, a multikinase inhibitor, was designed to identify maximal tolerated doses, safety, pharmacokinetics, and ... -
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Jones, R; Plummer, R; Moreno, V; Carter, L; Roda, D; et al. (AMER ASSOC CANCER RESEARCH, 2023-01-17)PURPOSE: This was a Phase I/II trial of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 given in combination with gemcitabine. Its objectives were to establish the safety profile, recommended Phase 2 dose (RP2D), ... -
A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer.
Georgiou, A; Stewart, A; Vlachogiannis, G; Pickard, L; Valeri, N; et al. (SPRINGER, 2021-08-30)PURPOSE: We hypothesised that plasticity in signal transduction may be a mechanism of drug resistance and tested this hypothesis in the setting of cetuximab resistance in patients with KRAS/NRAS/BRAFV600 wild-type colorectal ... -
A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic.
Tiu, C; Shinde, R; Yap, C; Rao Baikady, B; Banerji, U; et al. (ELSEVIER SCIENCE INC, 2020-07-01) -
A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials.
Ingles Garces, AH; Ang, JE; Ameratunga, M; Chénard-Poirier, M; Dolling, D; et al. (ELSEVIER SCI LTD, 2018-11-01)BACKGROUND: The incidence and clinical significance of electrolyte abnormalities (EAs) in phase I clinical trials are unknown. The objective of this study is to evaluate the incidence and severity of EAs, graded according ... -
A study of motivations and expectations of patients seen in phase 1 oncology clinics.
Dolly, SO; Kalaitzaki, E; Puglisi, M; Stimpson, S; Hanwell, J; et al. (WILEY-BLACKWELL, 2016-11-15)BACKGROUND: To better inform clinical practice, this study was aimed at capturing patients' motivations for enrolling in phase 1 trials and at quantifying their expectations of the benefits, risks, and commitment associated ... -
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.
Minchom, A; Thavasu, P; Ahmad, Z; Stewart, A; Georgiou, A; et al. (PUBLIC LIBRARY SCIENCE, 2017-10-05)We investigated PD-L1 changes in response to MEK and AKT inhibitors in KRAS mutant lung adenocarcinoma (adeno-NSCLC). PD-L1 expression was quantified using immunofluorescence and co-culture with a jurkat cell-line transfected ... -
A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy.
Tiu, C; Shinde, R; Pal, A; Biondo, A; Lee, A; et al. (Innovative Healthcare Institute, 2021-11-01)INTRODUCTION: Immune checkpoint inhibitors (ICIs) are increasingly a standard of care for many cancers; these agents can result in immune-related adverse events (irAEs) including fever, which is common but can rarely be ... -
AKT Inhibition in Solid Tumors With AKT1 Mutations.
Hyman, DM; Smyth, LM; Donoghue, MTA; Westin, SN; Bedard, PL; et al. (AMER SOC CLINICAL ONCOLOGY, 2017-07-10)Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an ATP-competitive pan-AKT kinase inhibitor, to determine the preliminary ... -
Antibody-drug conjugates--an emerging class of cancer treatment.
Diamantis, N; Banerji, U (NATURE PUBLISHING GROUP, 2016-02-16)Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. New linker technology associated ... -
Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?
Roda, D; Jimenez, B; Banerji, U (AMER ASSOC CANCER RESEARCH, 2016-05-01)Tolerability of molecularly targeted agents (MTA) used in cancer therapeutics is determined in phase I trials. We reviewed the reported incidence of toxicity in phase III trials at doses and schedules recommended by phase ... -
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer.
Smyth, LM; Tamura, K; Oliveira, M; Ciruelos, EM; Mayer, IA; et al. (AMER ASSOC CANCER RESEARCH, 2020-08-01)PURPOSE: The activating mutation AKT1 E17K occurs in approximately 7% of estrogen receptor-positive (ER+) metastatic breast cancer (MBC). We report, from a multipart, first-in-human, phase I study (NCT01226316), tolerability ...